Article
A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
The pharmacogenomics journal - 1 Oct 2013
Han J-Y, Shin E S, Lee Y-S, Ghang H Y, Kim S-Y, Hwang J-A, Kim J Y, Lee J S
Abstract excerpt
The identification of patients who are at high risk for irinotecan-related severe diarrhea and neutropenia is clinically important. We conducted the first genome-wide association study (GWAS) to search for novel susceptibility genes for irinotecan-related severe toxicities, such as diarrhea and neutropenia, in non-small-cell lung cancer (NSCLC) patients treated with irinotecan chemotherapy. The GWAS putatively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.